In this week's video, Dr. Brian G.M. Durie explains how bispecific antibodies work and why they are being studied in clinical trials  to treat myeloma.

BOTTOM LINE:​
Bispecific antibodies are showing great promise in clinical trials.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org.

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Previous Post
New Guidelines for Superior Imaging, a Possible Cause of Post-Transplant Relapse, and the Future of Genetic Therapy: Myeloma News in Brief
Next Post
Second Asian Myeloma Network Summit in Beijing, China Is a Big Success

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.